Roche Receives FDA Approval for the First Companion Diagnostic to Assess PTEN Protein in People Living With Prostate Cancer
June 13, 2026
June 13, 2026
BASEL, Switzerland, June 13 -- Roche, a biotech company, issued the following news release on June 12, 2026:
* * *
Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer
* The new VENTANA PTEN (SP218) RxDx Assay fulfils an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with TRUQAP
* In prostate cance . . .
* * *
Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer
* The new VENTANA PTEN (SP218) RxDx Assay fulfils an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with TRUQAP
* In prostate cance . . .